<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736709</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-INF-4012</org_study_id>
    <nct_id>NCT01736709</nct_id>
  </id_info>
  <brief_title>The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine</brief_title>
  <official_title>A Single-centered, Open-labeled, Phase 4 Study of 2012-2013 Trivalent Seasonal Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of 2012-2013 trivalent
      seasonal influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged
      18-60 years old, and 60 healthy older people aged &gt; 60 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination inhibition (HI) antibody titer of 2012-2013 trivalent seasonal influenza vaccine</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>to evaluate the immunogenicity of the vaccine in adults and old people.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of systemic and local adverse reactions after vaccination</measure>
    <time_frame>0-21 days after vaccination</time_frame>
    <description>to evaluate the safety of the vaccine in healthy infants, adults, and old people</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>trivalent seasonal influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2012-2013 trivalent seasonal influenza vaccine</intervention_name>
    <description>trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people</description>
    <arm_group_label>trivalent seasonal influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For adults and old people:

        Inclusion Criteria:

          -  Healthy adults aged 18-60 years old, and healthy old people aged &gt;60 years

          -  Be able to show legal identity card for the sake of recruitment Without vaccination
             history of seasonal split influenza vaccine in the recent 3 years

          -  Not participate in any other clinical trials during the study

          -  Not receive any immunosuppressive agents during and one month prior to the study

          -  Be able to understand and sign the informed consent.

        Exclusion Criteria:

          -  Woman： Who breast-feeding or planning to become pregnant during the study

          -  Any history of allergic reactions; was allergic to any component of the vaccine, such
             as eggs or ovalbumin

          -  Any history of severe adverse reactions to vaccines, such as anaphylaxis, hives,
             respiratory difficulty, angioedema, or abdominal pain

          -  Autoimmune disease or immunodeficiency

          -  Acute episode of chronic diseases or conditions, including chronic hepatitis,
             hypertension, diabetes mellitus and cardiovascular diseases

          -  Guillain-Barre Syndrome

          -  Women subjects with positive urinary pregnancy test

          -  Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months (with the exception of corticosteroid nasal
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated
             dermatitis)

          -  Axillary temperature &gt;37.0 centigrade at the time of dosing

          -  Psychiatric condition that precludes compliance with the protocol; past or present
             psychoses; past or present bipolar disorder requiring therapy that has not been well
             controlled on medication for the past two years; disorder requiring lithium; or
             suicidal ideation occurring within five years prior to enrollment

          -  Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent.

        For infants:

        Inclusion Criteria:

          -  Healthy male or female aged between 6 and 35 months

          -  Full-term birth, birth weight 2,500 grams or more

          -  provided birth certification or vaccination card Parent(s) or legal guardian(s) are
             able to understand and sign the informed consent

        Exclusion Criteria:

          -  Administration of 2012-2013 seasonal vaccine

          -  Subject that has a medical history of any of the following: allergic history, or
             allergic to any ingredient of vaccine, such as egg, egg protein, etc

          -  Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain

          -  Symptoms of acute infection within a week

          -  Autoimmune disease or immunodeficiency

          -  Congenital malformation, developmental disorders or serious chronic diseases (such as
             Down's syndrome, diabetes, sickle cell anemia or neurological disorders)

          -  Asthma that is unstable or required emergent care, hospitalization or intubation
             during the past two years or that required the use of oral or intravenous
             corticosteroids

          -  Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with Intramuscular injections or blood draws

          -  History or family history of convulsions, epilepsy, brain disease and psychiatric

          -  Asplenia, functional asplenia or any condition resulting in the absence or removal of
             the spleen

          -  Guillain-Barre Syndrome

          -  History of any blood products within 3 months

          -  Administration of any other investigational research agents within 30 days

          -  Administration of any live attenuated vaccine within 30 days

          -  Administration of subunit or inactivated vaccines within 14 days

          -  Be receiving anti-Tuberculosis prophylaxis or therapy currently

          -  Axillary temperature &gt; 37.0 centigrade at the time of dosing

          -  Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan-Shen Guo, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Center for Diseases Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henan Center for Diseases Control and Prevention</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>2012-2013 trivalent seasonal influenza vaccine</keyword>
  <keyword>immunogenicity,</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

